These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruption. Emileh A; Tuzer F; Yeh H; Umashankara M; Moreira DR; Lalonde JM; Bewley CA; Abrams CF; Chaiken IM Biochemistry; 2013 Apr; 52(13):2245-61. PubMed ID: 23470147 [TBL] [Abstract][Full Text] [Related]
44. Sulfotyrosine dipeptide: Synthesis and evaluation as HIV-entry inhibitor. Ju T; Hu D; Xiang SH; Guo J Bioorg Chem; 2016 Oct; 68():105-11. PubMed ID: 27475281 [TBL] [Abstract][Full Text] [Related]
45. Structure-function study and anti-HIV activity of synthetic peptide analogues derived from viral chemokine vMIP-II. Luo Z; Fan X; Zhou N; Hiraoka M; Luo J; Kaji H; Huang Z Biochemistry; 2000 Nov; 39(44):13545-50. PubMed ID: 11063591 [TBL] [Abstract][Full Text] [Related]
46. Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection. Tamamura H; Imai M; Ishihara T; Masuda M; Funakoshi H; Oyake H; Murakami T; Arakaki R; Nakashima H; Otaka A; Ibuka T; Waki M; Matsumoto A; Yamamoto N; Fujii N Bioorg Med Chem; 1998 Jul; 6(7):1033-41. PubMed ID: 9730240 [TBL] [Abstract][Full Text] [Related]
47. Design, synthesis and activity evaluation of novel peptide fusion inhibitors targeting HIV-1 gp41. Tan J; Su M; Zeng Y; Wang C Bioorg Med Chem; 2016 Jan; 24(2):201-6. PubMed ID: 26706116 [TBL] [Abstract][Full Text] [Related]
48. The HIV-1 capsid protein as a drug target: recent advances and future prospects. Domenech R; Neira JL Curr Protein Pept Sci; 2013 Dec; 14(8):658-68. PubMed ID: 24106962 [TBL] [Abstract][Full Text] [Related]
49. The capsid protein of human immunodeficiency virus: designing inhibitors of capsid assembly. Neira JL FEBS J; 2009 Nov; 276(21):6110-7. PubMed ID: 19825045 [TBL] [Abstract][Full Text] [Related]
50. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds. Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646 [TBL] [Abstract][Full Text] [Related]
51. Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Rawal RK; Tripathi R; Katti SB; Pannecouque C; De Clercq E Eur J Med Chem; 2008 Dec; 43(12):2800-6. PubMed ID: 18242784 [TBL] [Abstract][Full Text] [Related]
52. Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor. Curreli F; Haque K; Xie L; Qiu Q; Xu J; Yong W; Tong X; Debnath AK Bioorg Med Chem; 2015 Dec; 23(24):7618-28. PubMed ID: 26602829 [TBL] [Abstract][Full Text] [Related]
53. SJP-L-5, a novel small-molecule compound, inhibits HIV-1 infection by blocking viral DNA nuclear entry. Bai R; Zhang XJ; Li YL; Liu JP; Zhang HB; Xiao WL; Pu JX; Sun HD; Zheng YT; Liu LX BMC Microbiol; 2015 Dec; 15():274. PubMed ID: 26630969 [TBL] [Abstract][Full Text] [Related]
54. Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors. Li X; Zhan P; Liu H; Li D; Wang L; Chen X; Liu H; Pannecouque C; Balzarini J; De Clercq E; Liu X Bioorg Med Chem; 2012 Sep; 20(18):5527-36. PubMed ID: 22883027 [TBL] [Abstract][Full Text] [Related]
55. Short constrained peptides that inhibit HIV-1 entry. Sia SK; Carr PA; Cochran AG; Malashkevich VN; Kim PS Proc Natl Acad Sci U S A; 2002 Nov; 99(23):14664-9. PubMed ID: 12417739 [TBL] [Abstract][Full Text] [Related]
56. Potent anti-HIV-1 activity of N-HR-derived peptides including a deep pocket-forming region without antagonistic effects on T-20. Izumi K; Watanabe K; Oishi S; Fujii N; Matsuoka M; Sarafianos SG; Kodama EN Antivir Chem Chemother; 2011 Aug; 22(1):51-5. PubMed ID: 21860071 [TBL] [Abstract][Full Text] [Related]
57. CD4 mimics as HIV entry inhibitors: lead optimization studies of the aromatic substituents. Narumi T; Arai H; Yoshimura K; Harada S; Hirota Y; Ohashi N; Hashimoto C; Nomura W; Matsushita S; Tamamura H Bioorg Med Chem; 2013 May; 21(9):2518-26. PubMed ID: 23535561 [TBL] [Abstract][Full Text] [Related]
58. Protein design of an HIV-1 entry inhibitor. Root MJ; Kay MS; Kim PS Science; 2001 Feb; 291(5505):884-8. PubMed ID: 11229405 [TBL] [Abstract][Full Text] [Related]
59. Design, synthesis and biological evaluation of (E)-3,4-dihydroxystyryl 4-acylaminophenethyl sulfone, sulfoxide derivatives as dual inhibitors of HIV-1 CCR5 and integrase. Sun Y; Xu W; Fan N; Sun X; Ning X; Ma L; Liu J; Wang X Bioorg Med Chem; 2017 Feb; 25(3):1076-1084. PubMed ID: 28082070 [TBL] [Abstract][Full Text] [Related]
60. Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities. Sun L; Dick A; Meuser ME; Huang T; Zalloum WA; Chen CH; Cherukupalli S; Xu S; Ding X; Gao P; Kang D; De Clercq E; Pannecouque C; Cocklin S; Lee KH; Liu X; Zhan P J Med Chem; 2020 May; 63(9):4790-4810. PubMed ID: 32298111 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]